Compare Roku Inc. Class A Common Stock (ROKU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roku Inc. Class A Common Stock vs Tango Therapeutics Inc. — how do they compare? Roku Inc. Class A Common Stock trades at $152.43 (market cap $22.67B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Roku Inc. Class A Common Stock is far larger — about 6× Tango Therapeutics Inc.'s market cap, and Roku Inc. Class A Common Stock is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roku Inc. Class A Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| ROKU | TNGX | |
|---|---|---|
Market Cap | $22.67B | $3.75B |
Volume | 1,039,228 | 9,619,106 |
Sector | Media | Health |
52-Week High | $159.76 | $32.90 |
52-Week Low | $82.93 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $20.59B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roku trades at $152.66, down slightly by 0.1% today. The stock shows mixed technical signals with a neutral overall rating. Fundamentally, revenue growth is solid with 2026 projections at $5.2B, while profitability improved significantly with net income margin rising to 6.81%. Recent earnings beats and the pending Fox acquisition approval highlight positive momentum. Analyst consensus is evenly split between Buy and Hold with a $161.38 price target.
Outlook remains cautiously optimistic with strong earnings performance and acquisition synergies offering upside potential. Key risks include regulatory scrutiny of the Fox deal, competitive pressures in streaming, and negative cash flow trends. The stock presents a growth opportunity if execution continues, but investors should monitor acquisition progress and profitability sustainability.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Roku Inc. Class A Common Stock
Roku operates a streaming platform that combines its operating system, streaming devices, TV partnerships, and advertising services. It connects viewers with streaming content and services.
Read more on ROKU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
